Radio-potentiation via PARP- or alternatively DNA-PK-inhibition potentially bears valuable clinical benefit, as it would lack systemic toxicity and could improve the outcome for inoperable, large or axial Ewing sarcomas. Here, PRKDC is linked to Ewing sarcoma.